Sequoia's Valeant bet hard lesson for investors - 03/29/2016

In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch.

Share Feedback Post on LinkedIn Share Article

Most Read

Top of the Agenda - Governance
ASA board enlarged, timeline to AGM unclear

ASA Gold and Precious Metals Ltd. shareholders voted at a special meeting last week to enlarge the closed-end fund's board and elected a fifth independent director, one ...

A Seat at the Table
Cooking, breaking bread builds Heartland Funds board-advisor relations

Members of the Heartland Funds board and Heartland Advisors management team spent a recent evening together sharing a meal. Of course it's not unusual for independent ...

Top of the Agenda - Compensation
Fund directors earned more in 2024, MPI survey finds

Average compensation among mutual fund independent directors was higher in 2024, when compared to the year prior, an increase that was more than double what their ...

Viewpoints
Sub-Adviser AI Oversight: Focus on what matters

Comprehensive guidance on the oversight of sub-advisers that exists in the market has served mutual fund boards well for over 15 years. These frameworks remain foundational, ...